[go: up one dir, main page]

CO2018005367A2 - Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo campo técnico - Google Patents

Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo campo técnico

Info

Publication number
CO2018005367A2
CO2018005367A2 CONC2018/0005367A CO2018005367A CO2018005367A2 CO 2018005367 A2 CO2018005367 A2 CO 2018005367A2 CO 2018005367 A CO2018005367 A CO 2018005367A CO 2018005367 A2 CO2018005367 A2 CO 2018005367A2
Authority
CO
Colombia
Prior art keywords
azaindolin
derivative
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
Prior art date
Application number
CONC2018/0005367A
Other languages
English (en)
Inventor
Byeong-Seon Jeong
Jung-Ae Kim
Tae-Gyu Nam
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of CO2018005367A2 publication Critical patent/CO2018005367A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

RESUMEN DE LA INVENCIÓN La presente invención se relaciona a un derivado de 7-azaindolin-2-ona o una sal farmacéuticamente aceptable del mismo, y el derivado de 7-azaindolin-2-ona o la sal farmacéuticamente aceptable del mismo se puede utilizar favorablemente como un material medicinal para inhibir el crecimiento de cáncer y metástasis de cáncer.
CONC2018/0005367A 2015-11-12 2018-05-23 Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo campo técnico CO2018005367A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150158695 2015-11-12
PCT/KR2016/012409 WO2017082569A1 (ko) 2015-11-12 2016-10-31 7-아자인돌린-2-온 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 약학 조성물

Publications (1)

Publication Number Publication Date
CO2018005367A2 true CO2018005367A2 (es) 2018-06-12

Family

ID=58695675

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0005367A CO2018005367A2 (es) 2015-11-12 2018-05-23 Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo campo técnico

Country Status (18)

Country Link
US (1) US10544140B2 (es)
EP (1) EP3363799A4 (es)
JP (1) JP6661766B2 (es)
KR (1) KR102109869B1 (es)
CN (1) CN108368108B (es)
AU (1) AU2016353573B2 (es)
BR (1) BR112018009482A2 (es)
CA (1) CA3004595A1 (es)
CL (1) CL2018001236A1 (es)
CO (1) CO2018005367A2 (es)
EA (1) EA201891136A1 (es)
IL (1) IL259083A (es)
MA (1) MA42361A1 (es)
MX (1) MX2018005894A (es)
NZ (1) NZ742228A (es)
PH (1) PH12018500946A1 (es)
WO (1) WO2017082569A1 (es)
ZA (1) ZA201803722B (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
JP2002522452A (ja) * 1998-08-04 2002-07-23 スージェン・インコーポレーテッド 蛋白質キナーゼの調節剤３−メチリデニル−２−インドリノン
ATE299881T1 (de) 1999-12-21 2005-08-15 Sugen Inc 4-substituierte 7-aza-indolin-2-one und ihre anwendung als protein kinase inhibitoren
KR101375156B1 (ko) * 2008-05-23 2014-03-18 쟝수 치아타이 티안큉 파마수티컬 주식회사 디하이드로인돌리논 유도체들
HUE046368T2 (hu) * 2012-01-26 2020-02-28 Angion Biomedica Corp Anti-fibrotikus vegyületek és alkalmazásuk
US10485800B2 (en) * 2012-11-30 2019-11-26 The University Of Rochester Mixed lineage kinase inhibitors for HIV/AIDS therapies
AU2014243869A1 (en) * 2013-03-13 2015-09-24 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
US9187454B2 (en) * 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
CN104876928B (zh) * 2015-05-07 2016-09-14 浙江司太立制药股份有限公司 7-氮杂吲哚啉-2-酮类化合物及其制备方法

Also Published As

Publication number Publication date
WO2017082569A1 (ko) 2017-05-18
EP3363799A1 (en) 2018-08-22
CA3004595A1 (en) 2017-05-18
CN108368108A (zh) 2018-08-03
US20180370964A1 (en) 2018-12-27
CN108368108B (zh) 2021-09-21
AU2016353573A1 (en) 2018-05-24
BR112018009482A2 (pt) 2018-11-06
JP2018533600A (ja) 2018-11-15
MA42361A1 (fr) 2018-09-28
EP3363799A4 (en) 2018-12-05
US10544140B2 (en) 2020-01-28
AU2016353573B2 (en) 2019-11-21
EA201891136A1 (ru) 2018-10-31
JP6661766B2 (ja) 2020-03-11
NZ742228A (en) 2019-09-27
MX2018005894A (es) 2018-08-15
CL2018001236A1 (es) 2018-08-24
ZA201803722B (en) 2019-03-27
IL259083A (en) 2018-06-28
PH12018500946A1 (en) 2018-11-12
KR20170056430A (ko) 2017-05-23
KR102109869B1 (ko) 2020-05-13

Similar Documents

Publication Publication Date Title
ZA202308496B (en) Pharmaceutical compositions of therapeutically active compounds
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
MX2017002028A (es) Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7).
BR112016026291A2 (pt) Derivados do ácido borônico e usos terapêuticos dos mesmos
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
PH12016501788B1 (en) Pharmaceutical compositions of therapeutically active compounds
MX2018005725A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
MX2017016149A (es) Compuestos triciclicos y su uso como inhibidores de la fosfodiesterasa.
MX2017007699A (es) Formulacion de proporcion fija de insulina glargina/lixisenatida.
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
SV2016005331A (es) Derivados de naftiridinadiona
CL2016001843A1 (es) Uso de una composición que comprende a) un compuesto de fórmula (ia) definida o una sal del mismo y b) un portador o excipiente farmacéuticamente aceptable para preparar un medicamento útil para tratar una afección alérgica en un mamífero.
CO2018005367A2 (es) Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo campo técnico
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
ZA201606135B (en) Pharmaceutical compositions of therapeutically active compounds
MX383685B (es) Clonidina y/o derivados de clonidina para uso en la prevención de la lesión de la piel resultante de la radioterapia.
HK1233185A1 (en) Pharmaceutical compositions of therapeutically active compounds
HK1233909A1 (en) Pharmaceutical compositions of therapeutically active compounds
UA112089C2 (uk) Тверда лікарська форма комбінованого препарату седативної та снодійної дії, що містить доксиламін